Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of Alzheimer's disease

Patent metadata

Field	Value
Publication number	US-11274125-B2
Application number	US-202016908606-A
Country	US
Kind code	B2
Filing date	Jun 22, 2020
Priority date	Sep 26, 2013
Publication date	Mar 15, 2022
Grant date	Mar 15, 2022

Abstract

The invention relates to amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.

First claim

The invention claimed is:

1. A peptide comprising an amino acid sequence which binds to amyloid beta species,
wherein the peptide has been modified by cyclization,
wherein the amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and homologs thereof, with an identity of at least 80%, and
wherein the peptide's binding affinity to the amyloid beta species is increased as compared to an analogous peptide without any modification.

2. The peptide according to claim 1 , wherein D-enantiomeric amino acids make up at least 50% of the amino acid sequence.

3. The peptide according to claim 1 , being linked to a further substance.

4. The peptide according to claim 1 , comprising at least two amino acid sequences, one of which is SEQ ID NO: 1 and the other being selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12 and homologs thereof.

5. The peptide according to claim 4 , wherein the at least two amino acid sequences together form a second amino acid sequence selected from the group consisting of SEQ ID NO: 4 and SEQ ID NO: 5, and homologs thereof.

6. A method for producing a peptide according to claim 1 , comprising a step of producing the peptide by way of peptide synthesis or mutagenesis.

7. A kit comprising a peptide according to claim 1 .

8. A composition comprising a peptide according to claim 1 .

Assignees

• Forschungszentrum Juelich Gmbh
• Priavoid Gmbh

Inventors

• Willbold Dieter

Classifications

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K14/00

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title

• A61K38/16

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title